We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interferon Gamma Assay Detects Chronic Q Fever

By LabMedica International staff writers
Posted on 17 Jul 2013
The diagnosis of Q fever, caused by the intracellular pathogen Coxiella burnetii, relies mainly on serology and skin tests (STs)—both with drawbacks.

A C. More...
burnetii-specific interferon gamma (IFN-γ) production has been used as a diagnostic tool for past Q fever infection that circumvented most of these shortcomings, and was compared with serology and ST.

Scientists at the Radboud University (Nijmegen, The Netherlands) enrolled 1,525 individuals from an endemic area with a risk for chronic Q fever. IFN-γ production was measured after in vitro stimulation of whole blood with C. burnetii antigens. Various formats using different C. burnetii antigens were tested and serology and ST were performed on all individuals.

The amount of IFN-γ was measured by enzyme-linked immunosorbent assay (ELISA). Serological and ST results were unknown to those performing the assay. Net IFN-γ production was expressed as the concentration of IFN-γ in stimulated samples minus that in negative controls. If either IFN-γ production in the negative control exceeded 24 pg/mL, which is three times the lower detection limit of the ELISA, or the IFN-γ production after phytohemagglutinin (PHA) stimulation was less than24 pg/mL without the C. burnetii-stimulated aliquots exceeding 24 pg/mL, then the assay was considered inconclusive.

In all assay formats, C. burnetii-specific IFN-γ production was higher in seropositive or ST-positive subjects than in seronegative and ST-negative subjects. Whole blood incubated for 24 hours with the heat-inactivated laboratory C. burnetii Nine Mile strain showed optimal performance. After excluding subjects with equivocal serology and/or borderline ST results, IFN-γ production was 449 ± 82 pg/mL in 219 positive individuals, but only 21 ± 3 pg/mL in 908 negative subjects. The IFN-γ assay had a sensitivity of 87.0% and the specificity was 90.2%, which was similar to the combination of serology and ST at 83.0% sensitivity and 95.6% specificity.

The authors concluded that specific IFN-γ detection is a novel diagnostic assay for previous C. burnetii infection and shows similar performance and practical advantages over serology and ST. However, they recommend that the assay as being complimentary to serological tests, with added value in cases with equivocal serology. The additional value of the assay in active Q fever disease, both the acute and chronic form, is currently being addressed. The study was originally published online on March 5, 2013, in the journal Clinical Infectious Diseases.

Related Links:

Radboud University




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Clinical Chemistry

view channel
Image: The steps involved in the electric field-induced capture and release (EFIRM) assay (Photo courtesy of UCLA School of Dentistry)

Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation

Early detection of cancer and other serious diseases is crucial for effective treatment and improved outcomes, yet current diagnostic methods often involve invasive procedures and complex sample preparation.... Read more

Molecular Diagnostics

view channel
Image: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is FDA-cleared for use in diagnosing Alzheimer’s (Photo courtesy of Fujirebio)

First FDA Cleared Blood Test for Alzheimer’s Diagnosis Marks Turning Point in Early Detection

Alzheimer’s disease is a progressive form of dementia that affects memory, cognition, and behavior, eventually interfering with daily activities. Early and accurate diagnosis is essential to improving... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.